Fundraising FoxNYBC Ventures
Corporate VCNew York · Seed–Series B · 8 people tracked
Find your way into NYBC Ventures
Sign up to see every warm intro you have to NYBC Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NYBC Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
NYBC Ventures is a corporate venture fund launched by New York Blood Center Enterprises with a $50M commitment to accelerate breakthroughs in blood and cellular therapies and supporting technologies. It leverages New York Blood Center's decades of expertise in blood products, transfusion services, and cell and gene therapy manufacturing. The fund targets early to mid stage innovations across hematology, transfusion medicine, cell therapy, and infectious disease, supporting therapeutics, devices, and other breakthrough solutions that address key challenges in these fields and ultimately improve patient lives.
Source: firm website, verified Aug 7, 2026.
Team · 8 people
from the firm's website & public directories
President and CEO of New York Blood Center Enterprises and founder of NYBC Ventures, Hillyer is an internationally recognized expert in hematology, transfusion, transplantation, and cellular/gene therapies with extensive executive and scientific leadership experience.
EVP and Chief Business Officer at NYBCe, Mohr co-manages NYBC Ventures and brings over 30 years of biopharmaceutical executive experience in capital formation, business development, and corporate strategy. He serves as a board observer to several portfolio companies.
Wood focuses on identifying and supporting innovative companies for NYBC Ventures, contributing to investment strategy and portfolio growth. She holds a master's degree from Boston University's School of Public Health.
Csimma is a biopharmaceutical leader with decades of experience in global drug development, new company formation, and venture capital. She serves on several biotech boards and was previously a principal at Clarus Ventures.
Kabakoff, PhD, is an organic and biochemist with over 30 years in pharma technology development and 18 years as a venture investor. He is an Executive Partner at Sofinnova Investments and Founding Senior Partner of HealthQuest Capital.
Rosenthal is EVP and Chief Investment Officer of Brighthouse Financial and previously spent 32 years at MetLife. A CFA charterholder, he has been a Trustee of the New York Blood Center since 2018.
Choi is a biotech executive and board member who served as chief business and strategy officer for Global Blood Therapeutics and was instrumental in its $5.8B acquisition by Pfizer. She is an entrepreneur-in-residence at Third Rock Ventures with prior venture capital and strategy experience.
Yu joined NYBC Ventures in 2024 to identify and assess companies in the firm's core focus areas, bringing a background in life sciences investment banking and consulting. He holds two bachelor's degrees from the Wharton School and the Vagelos Life Sciences and Management Program.
What they invest in
from 15 of 17 portfolio companiesBiotech ×13Healthtech ×10Medical Devices ×10Deep Tech ×6Longevity ×3Advanced Manufacturing ×2Digital Health ×2Robotics ×2
HQs:United States×10United Kingdom×1Netherlands×1
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×32 founders×43 founders×1
Investments · 17 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 12024 · 22019 · 12018 · 17 dated
STRM.BIO develops technology to deliver gene therapies, aiming to improve how these treatments reach patients.
BiotechDeep TechHealthtechLongevityMedical Devices
Michael Luther(CEO)in
Co-investorsAscension VenturesBreakout LabsBreakout VenturesDelos CapitalGaingelsBoehringer Ingelheim Venture Fund+2 more
__Twitter.png)
Akadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products.
Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesAnn Arbor, US
Kalyan Handique(Executive Officer, Director)John Younger(Executive Officer, Director)inJames Militello(Executive Officer)
BoardJeffrey S. Williams(Director)Paul D'Amato(Director)inDan Kidle(Director)in
Co-investorsArboretum VenturesBeringeaBerkeley CatalystBlueStone Venture PartnersCANTILEVER INVESTORSeLab Ventures+7 more
Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism.
BiotechDeep TechHealthtechPortland, US
Erik I. Tucker(President & Chief Executive Officer)in
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.
BiotechLongevityMedical Devices
Andrew Schiermeier(Chief Executive Officer)in
Co-investorsNovo HoldingsBlackstone Life SciencesEight Roads VenturesF-Prime Capital
CatenaBio develops precision conjugation technology using native amino acids to enable biotherapeutic fusions of small molecules, nucleic acids, enzymes, and cells.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Marco Lobba(Founder)inMatthew Francis(Founder)inGeo Guillen
Co-investorsCalifornia Innovation FundCivilization Ventures Management, LlcCreative Destruction Lab (CDL)FREEFLOWGaingelsIaso Ventures+14 more
Cellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.
Advanced ManufacturingBiotechRoboticsCambridge, GB
Alex Lang(Founder)
Co-investorsHighland EuropeTTP VenturesBusiness Growth FundJohnson & Johnson Innovation – JJDC
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in
Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesViking GlobalAltitude Ventures Management, LlcCasdin Capital+5 more
A blood bank and laboratory services provider supplying blood products including red blood cells, plasma, and platelets to hospitals and medical facilities, alongside laboratory testing services and specialty clinical procedures.
BiotechHealthtechMedical DevicesNew York, US
Functional Fluidics is a CLIA-certified diagnostic lab offering proprietary red blood cell function biomarker assays, starting with Sickle Cell Disease.
BiotechDigital HealthHealthtechMedical DevicesDetroit, US
Patrick Hines(CEO & Founder)inDr. Hines(Founder)John Cunningham(Chief Operating Officer)in
Co-investorsID VenturesMichigan RiseResilient VenturesSeae VenturesWavemaker Three-Sixty Health
A healthcare-focused investment firm managing approximately $2 billion in assets across 52 portfolio companies.
Digital HealthHealthtechMedical Devices
Co-investorsUnion Grove Venture Partners
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)inSean Ainsworth(Chief Executive Officer)inRobert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)inScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)in
Co-investorsBioRock VenturesBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital Network+6 more
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply.
BiotechDeep TechHealthtechMedical DevicesBaltimore, US
Allan Doctor(Co-Founder & CSO)inDipanjan Pan(Co-Founder, Chief Technical Officer)inPhilip Spinella(Co-Founder, Chief Medical Officer)inDaniel Getman(Director)Gregory Lanza(Director)
Co-investorsBioAdvanceBioGenerator VenturesDelaware Crossing Investor GroupMaryland TEDCOOld Line Capital PartnersTEDCO+1 more
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesViking Global+11 more
Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease.
AI & Machine LearningBiotechLongevityCambridge, US
Stan Wang(MD, PhD)inBing Lim(MD, PhD)inManish Jainin
Co-investorsPillar VC
Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
Co-investorsAlumni VenturesHatteras Venture PartnersPappas CapitalSanofi VenturesAlexandriaGenesys Capital+4 more
Vitestro is a Netherlands-based medical robotics company that develops Aletta, an autonomous robotic phlebotomy device for diagnostic blood collection in hospitals and laboratories.
HealthtechMedical DevicesRoboticsNetherlands, NL
Toon Overbeeke(Co-founder & CEO)inBrian Joseph(Co-founder)in
Co-investorsSonder CapitalIntervestInvest-NLMayo Clinic Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Vega Therapeutics
Exits · 1
1 acquisitionsVeraloxacq. by Cadrenal Therapeutics
Portfolio news
latest coverage across their companiesVitestro · yahoo.com · Aug 20, 2026
City Therapeutics · finsmes.com · Jun 9, 2026
Immusoft · immusoft.com · Mar 30, 2026
Star Therapeutics · star-therapeutics.com · Sep 30, 2025
Akadeum Life Sciences · biospace.com · Jun 4, 2025
Frequently asked questions
- How many investments has NYBC Ventures made?
- NYBC Ventures has 17 tracked investments, 1 of which have exited, including 4 dated in the last 24 months.
- What stage does NYBC Ventures invest at?
- NYBC Ventures invests at the Seed, Series A, Series B stages.
- What sectors does NYBC Ventures focus on?
- NYBC Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is NYBC Ventures located?
- NYBC Ventures is headquartered in New York, US.
- Does NYBC Ventures lead rounds?
- NYBC Ventures typically participates in rounds rather than leading them.
- Who does NYBC Ventures co-invest with?
- NYBC Ventures most often shares deals with Breakout Ventures, ID Ventures, Michigan Capital Network, among 41 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is an independent manager of venture capital funds and the listed investment company Quest for Growth, backing innovative companies that use technology as a competitive advantage.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.